Mike Tzuhen Wei, MD
Gastroenterology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Wei’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A150927 · Current
Licensed to practise in California · since 2017 · expires 2026-12-31 · Cornell University Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$117,358
Medicare paid this office $117,358 for 336 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 90 | $23,153 | $156 |
| Return visit (30+ min) | 120 | $20,116 | $111 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 69 | $16,285 | $233 |
| New patient visit (45+ min) | 61 | $7,951 | $130 |
| New patient visit (60+ min) | 36 | $6,286 | $175 |
See all 14 services
| Long return visit (40+ min) | 90 | $23,153 | $156 |
| Return visit (30+ min) | 120 | $20,116 | $111 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 69 | $16,285 | $233 |
| New patient visit (45+ min) | 61 | $7,951 | $130 |
| New patient visit (60+ min) | 36 | $6,286 | $175 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 60 | $5,515 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,183 | $149 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 27 | $3,960 | $116 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 21 | $3,622 | $172 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 119 | $2,423 | $15 |
| Short return visit (20+ min) | 25 | $2,018 | $72 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 22 | $1,863 | $81 |
| Biopsy of large bowel using a flexible endoscope | 32 | $1,716 | $52 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 54 | $271 | $5 |
Procedures Medicare counted
| Colonoscopy | 137 | More than 87% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 153 | More than 85% of doctors who do this |
Who their Medicare patients are
336 Original Medicare patients in 2024. Average age 72 · Under 65 12% · 85 and older 12% · Women 49% · Also on Medicaid 32% · Health risk score 1.63. Above the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 72% · Coronary heart disease 32% · Diabetes 30% · Atrial fibrillation 25% · Chronic kidney disease 23% · Cancer 22% · Heart failure 20% · Depression 18% · COPD 14% · Dementia 9% · Stroke 8%.
The office billed $1,147,829, Medicare allowed $151,588 and paid $117,358; for 1,073 services of 46 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 336 | 1,073 | 72 | 1.63 | $1,147,829 | $117,358 |
| 2023 | 323 | 860 | 72 | 1.91 | $778,070 | $90,539 |
| 2022 | 48 | 87 | 73 | 1.51 | $77,239 | $8,673 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 17 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 82 | $12,378 | $117 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 49 | $11,577 | $106 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 48 | $10,855 | $226 |
| Return visit (30+ min) | 76 | $9,268 | $86 |
| New patient visit (45+ min) | 79 | $8,404 | $106 |
| Long return visit (40+ min) | 38 | $6,170 | $112 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,509 | $157 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 31 | $2,593 | $84 |
| Short return visit (20+ min) | 37 | $2,581 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,852 | $71 |
| Biopsy of large bowel using a flexible endoscope | 29 | $1,818 | $63 |
| New patient visit (60+ min) | 13 | $1,624 | $125 |
| Biopsy of large bowel using a flexible endoscope | 11 | $1,338 | $122 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,272 | $85 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,256 | $97 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $1,244 | $104 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 44 | $206 | $5 |
2022: 1 service
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 15 | $65 | $4 |
Medicaid work
$55,112 in 2024
Medicaid paid $55,112 for 561 billed services this clinician did in 2024, up to 28 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| COLONOSCOPY W/LESION REMOVAL | 67 | $18,283 |
| Upper gastrointestinal endoscopy with biopsy | 105 | $13,135 |
| Return visit (30+ min) | 137 | $10,274 |
| TISSUE EXAM BY PATHOLOGIST | 108 | $6,871 |
| Long return visit (40+ min) | 56 | $5,937 |
| Fentanyl citrate injection | 88 | $611 |
| 2024 | 561 | 6 | 28 | $55,112 |
| 2023 | 326 | 7 | 23 | $20,310 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 155 | $7,546 |
| New patient visit (45+ min) | 77 | $6,783 |
| Upper gastrointestinal endoscopy with biopsy | 15 | $2,821 |
| TISSUE EXAM BY PATHOLOGIST | 17 | $1,318 |
| New patient visit (30+ min) | 12 | $850 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 37 | $616 |
| Short return visit (20+ min) | 13 | $376 |
Drugs they prescribed that Part D paid
$135,844
Pharmacies billed $135,844 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 616) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
490 generic and 126 brand-name prescriptions · $135,844 in drug cost · 29 antibiotic prescriptions to 18 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Linzess | 26 | $21,497 | $827 |
| Dexlansoprazole Dr | 30 | $7,194 | $240 |
| Esomeprazole Magnesium | 53 | $6,453 | $122 |
| Sucralfate | 13 | $3,359 | $258 |
| Colesevelam | 12 | $1,614 | $134 |
See all 12 drugs
| Linzess | 26 | $21,497 | $827 |
| Dexlansoprazole Dr | 30 | $7,194 | $240 |
| Esomeprazole Magnesium | 53 | $6,453 | $122 |
| Sucralfate | 13 | $3,359 | $258 |
| Colesevelam | 12 | $1,614 | $134 |
| Peg 3350-Electrolyte | 76 | $1,609 | $21 |
| Gavilyte-G | 70 | $1,317 | $19 |
| Omeprazole | 102 | $1,271 | $12 |
| Sod Sulf-Potass Sulf-Mag Sulf | 16 | $1,218 | $76 |
| Famotidine | 83 | $1,115 | $13 |
| Peg-3350 and Electrolytes | 27 | $546 | $20 |
| Pantoprazole | 16 | $203 | $13 |
Year by year
| 2024 | 616 | 282 | 0% (0) | 20% | $135,844 |
| 2023 | 392 | 190 | 0% (0) | 15% | $40,025 |
| 2022 | 180 | 74 | None | None | $24,809 |
| 2021 | 34 | 14 | 0% (0) | 38% | $16,035 |
| 2020 | 14 | None | 0% (0) | None | $1,999 |
| 2019 | 39 | 23 | None | None | $2,642 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Mesalamine | 14 | $5,359 | $383 |
| Omeprazole | 96 | $1,815 | $19 |
| Peg 3350-Electrolyte | 69 | $1,551 | $22 |
| Gavilyte-G | 51 | $991 | $19 |
| Famotidine | 38 | $822 | $22 |
| Peg-3350 and Electrolytes | 11 | $234 | $21 |
2022: 4 drugs
| Ampicillin-Sulbactam | 18 | $2,916 | $162 |
| Peg 3350-Electrolyte | 20 | $442 | $22 |
| Pantoprazole | 11 | $239 | $22 |
| Famotidine | 12 | $166 | $14 |
Money from drug and device companies
$174,823 in 2025
| 2025 | 1 | 10 | $174,823 | $174,823 |
| 2024 | 2 | 14 | $131,763 | $131,763 |
| 2023 | 4 | 13 | $38,300 | $41,395 |
| 2022 | 4 | 5 | None | $33,649 |
| 2021 | 1 | 1 | None | $122 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| CapsoVision | Capsocam Colon | $174,823 | 10 payments
|
See all 10 published payments
| CapsoVision | Consulting · 2025-12-18 | Capsocam Colon | $33,431 |
| CapsoVision | Consulting · 2025-12-05 | Capsocam Colon | $28,279 |
| CapsoVision | Consulting · 2025-10-24 | Capsocam Colon | $17,096 |
| CapsoVision | Consulting · 2025-08-27 | Capsocam Colon | $2,191 |
| CapsoVision | Consulting · 2025-08-06 | Capsocam Colon | $14,098 |
| CapsoVision | Consulting · 2025-08-06 | Capsocam Colon | $3,190 |
| CapsoVision | Consulting · 2025-07-09 | Capsocam Colon | $21,718 |
| CapsoVision | Consulting · 2025-05-21 | Capsocam Colon | $30,033 |
| CapsoVision | Consulting · 2025-04-03 | Capsocam Colon | $23,588 |
| CapsoVision | Consulting · 2025-01-02 | Capsocam Colon | $1,200 |
See earlier years (2024, 2023, 2022, 2021)
2024: $131,763
| CapsoVision | Capsocam Colon | $124,163 | 8 payments
|
| Neptune Medical | None | $7,600 | 1 payment
|
2023: $41,395
| CapsoVision | Capsocam Colon | $35,100 | 8 payments
|
| Neptune Medical | None | $3,200 | 1 payment
|
| Endogastric Solutions | Esophyx | $2,160 | 2 payments
|
| Ovesco Endoscopy USA | None | $935 | 1 payment
|
2022: $33,649
| Conmed | Conmed | $33,333 | 1 payment
|
| Olympus America | Endocuff Vision | $149 | 1 payment
|
| Boston Scientific | Exalt Model D | $136 | 2 payments
|
| Apollo Endosurgery US | X-Tack Endoscopic Helix Tacking System | $31 | 1 payment
|
2021: $122
| AbbVie | Humira | $122 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1417311408
- Licence
- CA A150927California A150927: Current · expires 2026-12-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2016-04-06
- NPI last updated
- 2024-04-12
- NPI record certified
- 2024-04-12
This is when the NPI record was last certified, not a medical board exam.